Anison Therapeutics is a preclinical-stage biotechnology company focused on developing innovative topical therapeutics for diseases associated with the Human Papillomavirus (HPV). We fight the HPV with a new treatment that targets-not the symptoms-but the root cause of the virus. Our initial focus is on formulating and commercializing topical treatments to address the unmet needs concerning genital warts and premalignant infections caused by HPV. Eventually, we aim to extend our focus on the treatment of a broader spectrum of warts and diseases driven by HPV.

By 2024, we anticipate initiating the preclinical phase of our pharmaceutical product development. Over the past year, our achievements include demonstrating API production feasibility, conducting light GMP production, creating prototypes, and performing proof of concept studies for our product. These significant milestones have set the stage for our next step: the preclinical program.

Our dedicated team with deep expertise in business, science, and commercialization of innovations, is committed to bringing our targeted HPV solutions to the market to address these widespread medical challenges effectively.

Beyond Symptom Relief: Anison’s HPV Therapeutic Vision

In the current medical landscape, there are no specific treatments for HPV infections, as existing interventions merely alleviate symptoms without targeting their root cause. Anison Therapeutics addresses this gap with an unwavering dedication to introducing an innovative treatment that directly targets HPV’s root cause. This nuanced approach goes beyond symptomatic relief, opening avenues for a potent therapeutic strategy beneficial for patients already grappling with HPV infections as well as those who have not been vaccinated. Our core technology, developed from decades of meticulous research on HPV by our co-founders at Åbo Akademi University in Finland, holds immense potential in treating various HPV-associated diseases, ranging from skin warts to premalignant infections. We aim to provide patients with safe and effective treatment options that can improve their quality of life.

Anison Team

A team of skilled professionals, diverse expertise, and insights from renowned experts

Our Team

Anison Focus

To eradicate HPV-associated diseases through a targeted portfolio

Discover Now

Anison Pipeline

GMP-controlled topical medication for genital warts and premalignant infections

Check It